Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: A randomized, controlled study in patients with early Type 2 diabetes

Diabetic Medicine

Volumn 27, Issue 2, 2010, Pages 175-180

  Hanefeld, M ^a   Koehler, C ^a   Hoffmann, C ^a   Wilhelm, K ^b   Kamke, W ^c   Gerstein, H ^d  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b Leipziger Institut für Präventivmedizin   (Germany)

^c MediClin Reha Zentrum Spreewald   (Germany)

^d HAMILTON HEALTH SCIENCES   (Canada)

Author keywords

Continuous glucose monitoring; Glargine insulin; Glycaemic variability; Hypoglycaemia; Type 2 diabetes

Indexed keywords

CREATININE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN GLARGINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PROSTAGLANDIN F2 ALPHA; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; GLARGINE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; INSULIN; LONG ACTING INSULIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GLYCEMIC LOAD; GROUPS BY AGE; HUMAN; HYPOGLYCEMIA; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PATIENT CARE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TEST MEAL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; AGED; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; CHEMICALLY INDUCED; DIABETES MELLITUS, TYPE 2; GLUCOSE TOLERANCE TEST; METABOLISM; MIDDLE AGED;

ADULT; AGED; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD;

EID: 76249126377     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2009.02915.x     Document Type: Article

References (21)

1. Punthakee Z, Werstuck GH, Gerstein HC. Diabetes and cardiovascular disease: explaining the relationship. Rev Cardiovasc Med 2007 8 : 145 153.
2. The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes Epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 1999 354 : 617 621.
3. Lawes CM, Parag V, Bennett DA, Suh I, Lam TH, Whitlock G et al. Asia Pacific Cohort Studies Collaboration Blood glucose and risk of cardiovascular disease in the Asia Pacific region. Diabetes Care 2004 27 : 2836 2842.
4. IDF. Guideline for Management of Postmeal Glucose. Brussels : International Diabetes Federation, 2007. Available at http://www.idf.org Last accessed 1 October 2009.
5. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M et al. ADVANCE Collaborative Group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008 358 : 2560 2572.
6. Gerstein HC, Miller ME, Byington RP, Goff DC Jr., Bigger JT, Buse JB et al. Action to Control Cardiovascular Risk in Diabetes Study Group Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008 358 : 2545 2559.
7. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Eng J Med 2009 360 : 129 139.
8. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 : 1577 1589.
9. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996 39 : 1577 1583.
10. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. J Am Med Assoc 2006 295 : 1681 1687.
11. Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J, Origin Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J 2008 155 : 26 32, 32.e1-32.e6.
12. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitudes of glycemic excursions, a measure of diabetes instability. Diabetes 1970 19 : 644 655.
13. Brynes AE, Lee JL, Brighton RE, Leeds AR, Dornhorst A, Frost GS. A low glycemic diet significantly improves the 24-h blood glucose profile in people with type 2 diabetes, as assessed using the continuous glucose MiniMed monitor. Diabetes Care 2003 26 : 548 549.
14. McNally PG, Dean JD, Morris AD, Wilkonson PD, Compion G, Heller SR. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. Diabetes Care 2007 30 : 1044 1048.
15. Chico A, Vidal-Ríos P, Subirà M, Novials A. The continuous glucose monitoring system is useful for detecting unrecognized hypoglycemia in patients with type 1 and type 2 diabetes, but is not better than frequent capillary glucose measurements for improving metabolic control. Diabetes Care 2003 26 : 1153 1157.
16. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 853.
17. Praet SF, Manders RJ, Meex RC, Lieverse AG, Stehouwer CD, Kuipers H et al. Glycaemic instability is an underestimated problem in type 2 diabetes. Clin Sci (Lond) 2006 111 : 119 126.
18. Monnier L, Colette C, Dunseath GJ, Owens DR. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 2007 30 : 263 269.
19. Bock G, Dalla Man C, Campioni M, Chittilapilly E, Basu R, Toffolo G et al. Pathogenesis of pre-diabetes: mechanisms of fasting and postprandial hyperglycemia in people with impaired fasting glucose and/or impaired glucose tolerance. Diabetes 2006 55 : 3536 3549.
20. Sargin M, Ikiisik M, Sargin H, Orcun A, Kaya M, Gözü H et al. The effect of defective early phase insulin secretion on postload glucose tolerance in impaired fasting glucose. Endocr J 2005 52 : 531 536.
21. Hanefeld M, Koehler C, Fuecker K, Henkel E, Schaper F, Temelkova-Kurktschiev T et al. Insulin secretion and insulin sensitivity pattern is different in isolated impaired glucose tolerance and impaired fasting glucose: the risk in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study. Diabetes Care 2003 26 : 868 874.